LENZ Therapeutics, Inc.
LENZ · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.80 | -0.74 | 3.16 |
| FCF Yield | -1.43% | -2.28% | -1.16% | -1.67% |
| EV / EBITDA | -46.71 | -40.59 | -50.98 | -46.82 |
| Quality | ||||
| ROIC | -8.41% | -8.76% | -7.41% | -5.97% |
| Gross Margin | 100.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.51 | 0.77 | 1.10 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,596,147.05% | 1,709,875.95% | -100.00% | -100.00% |
| Free Cash Flow Growth | 27.30% | -75.13% | 14.30% | 32.40% |
| Safety | ||||
| Net Debt / EBITDA | 2.17 | 1.29 | 1.24 | 3.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9,152.50 | -11,610.00 | -24,858.00 |